Towards seeing the visual impairments in Parkinson’s disease: protocol for a multicentre observational, cross-sectional study

BMC Neurology

  ^{1    1    1    1    2    3    3    3    4    5    5    6    6} 

[1] 0000 0000 8853 2677, grid.5361.1, Department of Neurology, Medical University Innsbruck, Innsbruck, Austria;0000 0000 8853 2677, grid.5361.1, Department of ophthalmology, Medical University Innsbruck, Innsbruck, Austria;0000 0004 0444 9382, grid.10417.33, Department of Neurology, Parkinson Center Nijmegen (ParC) Nijmegen, Donders institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, PO Box 9101, 6500, Nijmegen, HB, The Netherlands;0000000089452978, grid.10419.3d, Department of Ophthalmology, Leiden University Medical Centre, Leiden, The Netherlands;Department of Neurology, Onze Lieve Vrouw Gasthuis (OLVG), Amsterdam, The Netherlands;Radboud University Medical Centre, Department of Ophthalmology, Nijmegen, The Netherlands;

关键词: Parkinson’s disease;    Ophthalmology;    Eye;    Visual impairment;    Non-motor symptoms;    Screening questionnaire;    Survey;   

DOI  :  10.1186/s12883-019-1365-8

来源: publisher

【 摘 要 】

BackgroundVisual disorders are common in Parkinson’s disease (PD) but their exact frequency and severity are unknown. Good visual functioning is crucial for patients with PD, because of their need to compensate for loss of automated motor control and their postural instability, forcing patients to guide their movements visually. Here, we describe the study design of a cross-sectional, multi-centre study aiming to: (1) validate the Visual Impairment screening questionnaire (VIPD-Q, which aims to identify PD patients who should be referred to an ophthalmologist for further assessment); (2) study the prevalence of visual disorders in PD; (3) study the severity and clinical impact of different types of visual disorders in PD; and (4) explore treatment options for ophthalmologic disorders in PD, as a basis for future guideline development.MethodsThis study consists of two phases. In phase one, 750 PD patients and 250 healthy controls will be recruited to complete the VIPD-Q. In phase two, a subgroup of responders (n = 100) (with the highest and lowest scores on the VIPD-Q) will be invited for an extensive neurological and ophthalmological assessment. The in-depth ophthalmologic examination will serve as the “gold standard” for validating the VIPD-Q. Moreover, these assessments will be used to study associations between visual disorders and clinical presentation, in order to gain more insight in their clinical impact.DiscussionOur study will heighten the awareness of visual problems in PD and offers a robust starting point to systematically approach this subject. In current daily practice, the association between visual problems and PD is far from obvious to both patients and clinicians. Consequently, patients may not adequately report visual problems themselves, while clinicians miss potentially treatable visual disorders. Routinely asking patients to complete a simple screening questionnaire could be an easy solution leading to timely identification of visual problems, tailored treatment, restored mobility, greater independence and improved quality of life.Trial registrationDutch Trial Registration, NL7421, Registered on 4 December 2018 – Retrospectively registered.

【 授权许可】

CC BY